Enanta Pharmaceuticals | ENTA - Selling And Administration Expenses


Enanta Pharmaceuticals reported $-1.05 in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Biogen USD 554.3M 128.2M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Immunic USD 3.45M 451K Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Insmed USD 247.26M 34.78M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
J&J USD 6.03B 719M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
Merck USD 2.67B 180M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 2.92B 1.16B Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026